Robert C. Sergott, MD - oneGRAVESvoice

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Robert C. Sergott, MD

Healthcare Professional
Neuro-Ophthalmology Service
Wills Eye Hospital
840 Walnut Street, Suite 930
Philadelphia, Pennsylvania, United States

Robert C. Sergott is Chief of the neuro-ophthalmology service at Wills Eye Hospital and Professor of ophthalmology, neurology, and neurosurgery at Sidney Kimmel Medical College. In addition to these core appointments, Dr. Sergott is also an attending neuro-ophthalmologist at Lankenau Hospital in Philadelphia, and Chief Executive Officer of the Optic Nerve Research Center, headquartered in Claymont, Delaware.

Dr. Sergott earned both his undergraduate and medical degrees at Johns Hopkins University. He then completed a residency in ophthalmology at Wills Eye and a neuro-ophthalmology fellowship at Bascom-Palmer Eye Institute in Miami. In addition, he was a fellow in neuro-immunology and multiple sclerosis at the University of Pennsylvania School of Medicine in Philadelphia. 

Dr. Sergott’s clinical interests include optic neuropathies and multiple sclerosis, as well as the innovative field of tele-ophthalmology. He is a member of the American Academy of Ophthalmology; the North American Neuro-Ophthalmology Society (NANOS); and the International Neuro-Ophthalmologic Society.

Dr. Sergott has authored over 180 peer-reviewed publications, which included innovative therapies and technologies in the treatment of multiple sclerosis and carotid cavernous fistulas, innovative operative techniques such as optic nerve sheath decompression, and is an expert on new innovations in orbital color Doppler and optical coherence tomography. 


Representative Publications:

Orbital Radiotherapy for Thyroid-Related Orbitopathy

The Utility of Color Duplex Ultrasonography in the Diagnosis of Giant Cell Arteritis: A Prospective, Masked Study. (An American Ophthalmological Society Thesis)

Retrospective, Multicenter Comparison of the Clinical Presentation of Patients Presenting With Diplopia From Giant Cell Arteritis Vs Other Causes

Evaluation of Full-Field Electroretinogram Reductions After Ocriplasmin Treatment: Results of the Oasis Trial Erg Substudy

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.